Strs Ohio Takes $881,000 Position in Terns Pharmaceuticals, Inc. $TERN

Strs Ohio bought a new stake in Terns Pharmaceuticals, Inc. (NASDAQ:TERN) in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm bought 21,800 shares of the company’s stock, valued at approximately $881,000.

A number of other large investors have also added to or reduced their stakes in the stock. Commodore Capital LP purchased a new position in Terns Pharmaceuticals during the third quarter valued at $42,807,000. Vanguard Group Inc. raised its stake in Terns Pharmaceuticals by 21.1% during the fourth quarter. Vanguard Group Inc. now owns 5,523,948 shares of the company’s stock valued at $223,167,000 after buying an additional 964,031 shares during the last quarter. Geode Capital Management LLC raised its stake in Terns Pharmaceuticals by 3.8% during the second quarter. Geode Capital Management LLC now owns 1,633,349 shares of the company’s stock valued at $6,094,000 after buying an additional 59,145 shares during the last quarter. Pictet Asset Management Holding SA raised its stake in Terns Pharmaceuticals by 42.8% during the fourth quarter. Pictet Asset Management Holding SA now owns 1,577,116 shares of the company’s stock valued at $63,746,000 after buying an additional 472,912 shares during the last quarter. Finally, Adage Capital Partners GP L.L.C. purchased a new position in Terns Pharmaceuticals during the second quarter valued at $4,774,000. Hedge funds and other institutional investors own 98.26% of the company’s stock.

Insider Activity

In other Terns Pharmaceuticals news, CEO Amy L. Burroughs sold 14,583 shares of the business’s stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $46.71, for a total transaction of $681,171.93. Following the completion of the sale, the chief executive officer owned 288,976 shares of the company’s stock, valued at approximately $13,498,068.96. The trade was a 4.80% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Emil Kuriakose sold 942 shares of the business’s stock in a transaction dated Wednesday, April 1st. The shares were sold at an average price of $52.75, for a total value of $49,690.50. Following the sale, the insider directly owned 105,673 shares of the company’s stock, valued at $5,574,250.75. This represents a 0.88% decrease in their position. The disclosure for this sale is available in the SEC filing. Insiders have sold 30,108 shares of company stock valued at $1,302,370 in the last three months. 1.50% of the stock is currently owned by corporate insiders.

Terns Pharmaceuticals Price Performance

Shares of TERN opened at $52.95 on Friday. Terns Pharmaceuticals, Inc. has a one year low of $2.65 and a one year high of $53.19. The firm has a market capitalization of $6.12 billion, a P/E ratio of -51.41 and a beta of -0.37. The business has a fifty day moving average of $49.68 and a 200 day moving average of $37.90.

Terns Pharmaceuticals (NASDAQ:TERN) last issued its quarterly earnings data on Monday, March 30th. The company reported ($0.24) EPS for the quarter, topping the consensus estimate of ($0.30) by $0.06. Analysts expect that Terns Pharmaceuticals, Inc. will post -1.22 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of brokerages have issued reports on TERN. BMO Capital Markets cut Terns Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research note on Thursday, March 26th. Oppenheimer reiterated a “market perform” rating and set a $58.00 price objective on shares of Terns Pharmaceuticals in a research note on Monday, April 27th. Wall Street Zen cut Terns Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Saturday, March 21st. Barclays reiterated an “equal weight” rating and set a $53.00 price objective (down from $56.00) on shares of Terns Pharmaceuticals in a research note on Monday, March 30th. Finally, JPMorgan Chase & Co. lifted their price objective on Terns Pharmaceuticals from $44.00 to $44.50 and gave the company an “overweight” rating in a research note on Tuesday, April 14th. One equities research analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, ten have given a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and a consensus target price of $55.14.

About Terns Pharmaceuticals

Terns Pharmaceuticals, Inc is a clinical‐stage biopharmaceutical company focused on developing oral small‐molecule therapies for the treatment of chronic liver diseases and other serious conditions. The company’s research and development efforts center on novel mechanisms of action designed to address the underlying causes of progressive liver disorders, including inflammation, fibrosis and metabolic dysregulation. By advancing targeted compounds that can be administered orally, Terns aims to offer patients more convenient and effective treatment options compared to injectable or biologic therapies.

The company’s pipeline features several candidates in various stages of preclinical and clinical evaluation.